Targeting the Hepatic Stellate Cell Microenvironment: Nanomedicine Strategies for Liver Fibrosis Therapy
Molecular Pharmaceutics · 02.02.2026 · 23 (2) · 662-679
DOI: 10.1021/acs.molpharmaceut.5c01439 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Pharmaceutics, online erschienen am 23.12.2025. Verfasst von Lulu Pei und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, School of Pharmacy, Nantong University, Nantong, Jiangsu 226000, PR China. Hauptthemen laut MEDLINE: Hepatic Stellate Cells, Liver Cirrhosis, Nanomedicine, Cellular Microenvironment. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 175 Literaturangaben. Gefördert von: National Health and Medical Research Council (NHMRC) Early Career Fellowship, National Health and Medical Research Council, National Natural Science Foundation of China.
Abstract (Originalsprache)
Liver fibrosis, driven by hepatic stellate cells (HSCs) activation and pathological extracellular matrix (ECM) remodeling, involves dynamic crosstalk among macrophages, hepatocytes, liver sinusoidal endothelial cells (LSECs), and the fibrotic niche. In this perspective, we discuss the complex interactions among macrophages, hepatocytes, LSECs, ECM, and HSCs within the hepatic microenvironment, highlighting their role in liver fibrosis. Emerging nanomedicine strategies offer a promising solution through precision targeting, functionalization, and delivery optimization. This perspective highlights the pharmacological challenges of conventional therapies and underscores how nanomedicine overcomes biological barriers through enhanced biodistribution, reduced off-target effects, and combinatorial payload delivery. Future directions emphasize the need for patient stratification based on fibrosis etiology, the development of biomarker-guided smart nanosystems, and the clinical translation of microenvironment-remodeling approaches. By bridging mechanistic insights with cutting-edge drug delivery technologies, this work provides a roadmap for next-generation antifibrotic therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutics, School of Pharmacy, Nantong University, Nantong, Jiangsu 226000, PR China.
- NICM Health Research Institute, Western Sydney University, Sydney, New South Wales 2145, Australia.
ORCID-Profile: Tianqing Liu
Förderung
- National Health and Medical Research Council (NHMRC) Early Career Fellowship
- National Health and Medical Research Council
- National Natural Science Foundation of China
- Western Sydney University
Zitieren
APA
Pei, L., Du, X., Mao, Z., Ding, K., Li, J., Liu, T., & Zhao, Y. (2026). Targeting the Hepatic Stellate Cell Microenvironment: Nanomedicine Strategies for Liver Fibrosis Therapy. Molecular Pharmaceutics, 23(2), 662-679. https://doi.org/10.1021/acs.molpharmaceut.5c01439
Vancouver
Pei L, Du X, Mao Z, Ding K, Li J, Liu T, et al. Targeting the Hepatic Stellate Cell Microenvironment: Nanomedicine Strategies for Liver Fibrosis Therapy. Molecular Pharmaceutics. 2026;23(2):662-679. doi:10.1021/acs.molpharmaceut.5c01439
BibTeX
@article{Pei2026,
author = {Pei, Lulu and Du, Xing and Mao, Zehao and Ding, Kai and Li, Jiangyu and Liu, Tianqing and Zhao, Yongmei},
title = {Targeting the Hepatic Stellate Cell Microenvironment: Nanomedicine Strategies for Liver Fibrosis Therapy},
journal = {Molecular Pharmaceutics},
year = {2026},
volume = {23},
number = {2},
pages = {662--679},
doi = {10.1021/acs.molpharmaceut.5c01439}
}
EUVIMED